Gilles Soulat1, Kelly Jarvis1, Ashitha Pathrose1, Alireza Vali1, Michael Scott1,2, Amer A Syed1, Menhel Kinno3, Shyam Prabhakaran4, Jeremy D Collins5, Michael Markl1,2. 1. Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. 2. Department of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, Illinois, USA. 3. Loyola's Center for Heart & Vascular Medicine, Stritch School of Medicine, Loyola University Chicago, Chicago, Illinois, USA. 4. Neurology, The University of Chicago Biological Sciences, Chicago, Illinois, USA. 5. Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
BACKGROUND: Blood flow reversal is a possible mechanism for retrograde embolism in the setting of high-risk atherosclerotic plaques in the descending aorta (DAo). Evidence suggests that pulse wave velocity (PWV) is a determinant of blood flow reversal and can be reduced by the destiffening effect of renin-angiotensin system inhibitors (RASI). PURPOSE: To evaluate the impact of antihypertensive therapy on in vivo changes in PWV and flow reversal in patients with cryptogenic stroke. STUDY TYPE: Prospective. POPULATION: Sixteen patients (69 ± 9 years; 10 males) included after cryptogenic stroke. FIELD STRENGTH/SEQUENCE: 3T. 4D flow sequence (temporal resolution = 19.6 msec) ASSESSMENT: Patients underwent aortic MRI at baseline and at 6-month follow-up. Patients received standard-of-care antihypertensive therapy that were classified as RASI vs. non-RASI medications (ie, destiffening vs. nondestiffening).We compared aortic PWV, flow reversal fraction (FRF), aortic measurements, cardiac function, and other aortic and cardiac measurements in the antihypertensive therapy groups. STATISTICAL TESTS: Two-tailed paired or unpaired Student's t-tests (normal distributions) or Wilcoxon tests (nonnormal distribution). Univariate correlations using Pearson correlation coefficients. RESULTS: There was a significant decrease in PWV in the RASI (n = 10) group (9.4 ± 1.6 m/s vs. 8.3 ± 1.9 m/s; P < 0.05), as well as FRF (18.6% ± 4.1% vs. 16.3% ± 4.0%; P < 0.05) between baseline and the 6-month MRI studies. There were no changes in PWV or FRF in the non-RASI (n = 6) group (P = 0.146 and P = 0.32). A decrease in FRF was significantly correlated with a decrease in PWV (r = 0.53; P < 0.05). DATA CONCLUSION: The findings of our study suggest that RASI therapy after cryptogenic stroke resulted in a decrease of blood flow reversal and aortic stiffness. EVIDENCE LEVEL: 1 TECHNICAL EFFICACY STAGE: 4.
BACKGROUND: Blood flow reversal is a possible mechanism for retrograde embolism in the setting of high-risk atherosclerotic plaques in the descending aorta (DAo). Evidence suggests that pulse wave velocity (PWV) is a determinant of blood flow reversal and can be reduced by the destiffening effect of renin-angiotensin system inhibitors (RASI). PURPOSE: To evaluate the impact of antihypertensive therapy on in vivo changes in PWV and flow reversal in patients with cryptogenic stroke. STUDY TYPE: Prospective. POPULATION: Sixteen patients (69 ± 9 years; 10 males) included after cryptogenic stroke. FIELD STRENGTH/SEQUENCE: 3T. 4D flow sequence (temporal resolution = 19.6 msec) ASSESSMENT: Patients underwent aortic MRI at baseline and at 6-month follow-up. Patients received standard-of-care antihypertensive therapy that were classified as RASI vs. non-RASI medications (ie, destiffening vs. nondestiffening).We compared aortic PWV, flow reversal fraction (FRF), aortic measurements, cardiac function, and other aortic and cardiac measurements in the antihypertensive therapy groups. STATISTICAL TESTS: Two-tailed paired or unpaired Student's t-tests (normal distributions) or Wilcoxon tests (nonnormal distribution). Univariate correlations using Pearson correlation coefficients. RESULTS: There was a significant decrease in PWV in the RASI (n = 10) group (9.4 ± 1.6 m/s vs. 8.3 ± 1.9 m/s; P < 0.05), as well as FRF (18.6% ± 4.1% vs. 16.3% ± 4.0%; P < 0.05) between baseline and the 6-month MRI studies. There were no changes in PWV or FRF in the non-RASI (n = 6) group (P = 0.146 and P = 0.32). A decrease in FRF was significantly correlated with a decrease in PWV (r = 0.53; P < 0.05). DATA CONCLUSION: The findings of our study suggest that RASI therapy after cryptogenic stroke resulted in a decrease of blood flow reversal and aortic stiffness. EVIDENCE LEVEL: 1 TECHNICAL EFFICACY STAGE: 4.
Authors: Andreas Harloff; Jan Simon; Stefanie Brendecke; Dawit Assefa; Thomas Helbing; Alex Frydrychowicz; Johannes Weber; Manfred Olschewski; Christoph Strecker; Jürgen Hennig; Cornelius Weiller; Michael Markl Journal: Stroke Date: 2010-04-29 Impact factor: 7.914
Authors: Xin Shen; Susanne Schnell; Alex J Barker; Kenichiro Suwa; Lingzi Tashakkor; Kelly Jarvis; James C Carr; Jeremy D Collins; Shyam Prabhakaran; Michael Markl Journal: J Magn Reson Imaging Date: 2017-09-18 Impact factor: 4.813
Authors: Michael Markl; Wolf Wallis; Stefanie Brendecke; Jan Simon; Alex Frydrychowicz; Andreas Harloff Journal: Magn Reson Med Date: 2010-06 Impact factor: 4.668
Authors: Robert G Hart; Hans-Christoph Diener; Shelagh B Coutts; J Donald Easton; Christopher B Granger; Martin J O'Donnell; Ralph L Sacco; Stuart J Connolly Journal: Lancet Neurol Date: 2014-04 Impact factor: 44.182
Authors: Jeanette Schulz-Menger; David A Bluemke; Jens Bremerich; Scott D Flamm; Mark A Fogel; Matthias G Friedrich; Raymond J Kim; Florian von Knobelsdorff-Brenkenhoff; Christopher M Kramer; Dudley J Pennell; Sven Plein; Eike Nagel Journal: J Cardiovasc Magn Reson Date: 2013-05-01 Impact factor: 5.364